Wegovy is the latest brand-name version approved for weight loss in individuals who are overweight or have obesity with weight-related health conditions
Weight loss (by any means) causes a release of stored fat from fat cells, but the fat cells remain there as storage vessels, waiting for a calorie excess to fill back up again
Data are in line with results in randomised controlled trials and show the long-term stable benefit of once weekly semaglutide. Esther Walden, deputy head of care at Diabetes UK, said: This study suggests that improvements in blood sugars and weight loss can potentially be sustained in the longer term for adults with type 2 diabetes taking semaglutide as prescribed
How long does it take to switch from Wegovy to Mounjaro
But during the transition period, as blood sugar levels adjust, the immune system is adapting too
semaglutide was due to failure to meet HbA1c or weight targets with previous GLP-1 RAs, need to improve cardiovascular status and/or adherence (OW vs
